Evaxion Biotech Reports Q2 2025 Financial Results

Evaxion Biotech A/S Adr ( (EVAX) ) has released its Q2 earnings. Here is a breakdown of the information Evaxion Biotech A/S Adr presented to its investors.

Evaxion Biotech A/S is a clinical-stage TechBio company based in Copenhagen, Denmark, specializing in AI-Immunology™ powered vaccines for cancer, bacterial, and viral diseases. The company leverages artificial intelligence to decode the human immune system and develop novel immunotherapies.

In its second quarter 2025 earnings report, Evaxion Biotech A/S highlighted significant achievements, including the completion of patient treatments in the phase 2 trial of its personalized cancer vaccine EVX-01, and a grant from the Gates Foundation to explore a new polio vaccine. The company also announced a favorable debt-to-equity conversion agreement with the European Investment Bank, improving its financial position.

Key financial metrics showed a net loss of $4.8 million for the quarter, an improvement from the $6.2 million loss in the same period last year. The company’s cash position increased significantly, with cash and cash equivalents rising to $14.7 million as of June 30, 2025, from $6.0 million at the end of 2024. Evaxion’s R&D expenses decreased to $2.2 million, reflecting cost management efforts.

Strategically, Evaxion is focused on expanding its R&D pipeline and pursuing partnerships, with ongoing discussions and the potential for new deals in 2025. The company remains committed to its milestones and anticipates presenting two-year clinical data for EVX-01 at the ESMO Congress in October 2025.

Looking ahead, Evaxion’s management maintains a strong operational momentum and is optimistic about achieving further milestones and potential partnerships, despite challenges in the financial markets. The company’s strategic focus on AI-Immunology™ continues to drive interest and potential collaborations.